Literature DB >> 24997127

The oncologic role of local treatment in primary metastatic prostate cancer.

Pirus Ghadjar1, Alberto Briganti, Peter J L De Visschere, Jurgen J Fütterer, Gianluca Giannarini, Hendrik Isbarn, Piet Ost, Prasanna Sooriakumaran, Christian I Surcel, Roderick C N van den Bergh, Inge M van Oort, Ofer Yossepowitch, Guillaume Ploussard.   

Abstract

PURPOSE: To determine the oncologic benefit or otherwise of local treatment of the prostate in patients with primary metastatic prostate cancer.
METHODS: A review of the literature was performed in April 2014 using the Medline/PubMed database. Studies were identified using the search terms "prostate cancer," "metastatic," "metastasis," "high risk," "radiation therapy," "radiotherapy" and "prostatectomy" from 1990 until April, 2014. Articles were also identified through searches of references of these articles.
RESULTS: Retrospective series and population-based data suggest that the use of local treatment of the prostate in patients with primary metastatic prostate cancer may improve cancer-specific survival and overall survival compared with treating these patients with androgen deprivation therapy alone. The clinical outcome in metastatic prostate cancer is largely determined by the extent of lymph node involvement and overall metastatic burden. Contemporary data are lacking to recommend one alternative of local therapy (radiotherapy or radical prostatectomy) over the other. The primary limitation of this literature review is the lack of published randomized trial assessing the role of local treatment in addition to systemic therapy.
CONCLUSIONS: Local treatment appears to improve oncologic outcomes in metastatic prostate cancer patients. Nevertheless, due to the lack of high-quality evidence, its role needs to be confirmed in future prospective trials. The selection of ideal candidates and optimal treatment alternative (radiotherapy, radical prostatectomy or other) warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24997127     DOI: 10.1007/s00345-014-1347-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  35 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.

Authors:  Tracy R Glass; Catherine M Tangen; E David Crawford; Ian Thompson
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.

Authors:  Stephen A Boorjian; R Jeffrey Karnes; Rosalia Viterbo; Laureano J Rangel; Eric J Bergstralh; Eric M Horwitz; Michael L Blute; Mark K Buyyounouski
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

4.  Predicting survival of patients with node-positive prostate cancer following multimodal treatment.

Authors:  Firas Abdollah; R Jeffrey Karnes; Nazareno Suardi; Cesare Cozzarini; Giorgio Gandaglia; Nicola Fossati; Marco Bianchi; Stephen A Boorjian; Maxine Sun; Pierre I Karakiewicz; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2013-09-27       Impact factor: 20.096

5.  Use of surgery among elderly patients with stage IV colorectal cancer.

Authors:  Larissa K F Temple; Lillian Hsieh; W Douglas Wong; Leonard Saltz; Deborah Schrag
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

6.  Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial).

Authors:  Fritz H Schröder; Karl-Heinz Kurth; Sophie D Fossa; Wytse Hoekstra; Peter P Karthaus; Linda De Prijck; Laurence Collette
Journal:  Eur Urol       Date:  2008-09-17       Impact factor: 20.096

7.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

Review 8.  The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.

Authors:  Georgios Gakis; Stephen A Boorjian; Alberto Briganti; Steven Joniau; Guram Karazanashvili; R Jeffrey Karnes; Agostino Mattei; Shahrokh F Shariat; Arnulf Stenzl; Manfred Wirth; Christian G Stief
Journal:  Eur Urol       Date:  2013-05-22       Impact factor: 20.096

9.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321

Review 10.  Preparing the "soil": the premetastatic niche.

Authors:  Rosandra N Kaplan; Shahin Rafii; David Lyden
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

View more
  1 in total

1.  Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy.

Authors:  Isaac Yi Kim; Antonina Mitrofanova; Sukanya Panja; Joshua Sterling; Arnav Srivastava; Juliana Kim; Sinae Kim; Eric A Singer; Thomas L Jang; Saum Ghodoussipour; Biren Saraiya; Tina Mayer; Hatem E Sabaawy; Bertram Yuh; Seok Soo Byun; Wun-Jae Kim; Shigeo Horie
Journal:  Prostate Int       Date:  2022-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.